TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Life Sciences

    BiotechTV – News

    This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

    Advertise

    Copyright: © BiotechTV

    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    Two veterans from MPM have launched a new VC firm that will focus on investing in the I&I space - and it will leverage collaborations with disease specific philanthropies Dec 05, 2025
    Show notes

    Co-Founders Luke Evnin and Steven St. Peter describe the idea behind the firm, the value in partnering with philanthropies who know these diseases best, and why I&I is going through such a revolution currently.

    Oxford, UK based Accession Therapeutics raised $40M from existing investors today to further develop its precision viral delivered immunotherapies. The first program induces cancer cells to make PD-L1 Dec 04, 2025
    Show notes

    Founder and CEO Bent Jakobsen describes the science behind the platform, which he believes is unique in that it is delivered systemically, but is designed to bypass healthy tissue and only target tumor cells (without the need for screening). It targets the integrin αvβ6.

    From London: Cancer Research Horizons takes research from Cancer Research UK (and beyond) and invests in the translational work and companies that turn it into cures Nov 26, 2025
    Show notes

    CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty income to be reinvested in research. He describes the structure of the organization, a new startup fund, and some notable investments.

    Jefferies London: Ipsen has done a string of deals over recent years, including acquiring ImCheck last month. CEO David Loew says the company has billions in firepower to do more Nov 19, 2025
    Show notes

    He also goes over the company's programs in aesthetics, liver disease, and oncology.

    Jefferies London: Terns' CEO Amy Burroughs previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml Nov 19, 2025
    Show notes

    The data has been accepted for an oral presentation on Monday, December 8 and will be followed by a company webcast with more info.

    Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and walks us through a few of his firm's top positions Nov 19, 2025
    Show notes

    He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes.

    Jefferies London: Medicxi Announced a €500 Million Fund V ahead of this week's conference - Co-founder Giovanni Mariggi describes the firm's asset-centric approach to investing in biotech Nov 19, 2025
    Show notes

    He discusses the rationale behind the firm's asset-centric approach and highlights Vicebio as an example of how it works. Plus, his take on the current investment environment.

    Jefferies London: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset Nov 19, 2025
    Show notes

    Sean Bohen explains what he believes is the significance of the Roche announcement, and why he believes Olema's could potentially be a best in class oral SERD. Plus, a preview of data that will deliver sometime next year.

    Jefferies London: Zealand Pharma CEO Adam Steensberg believes that amylins will overtake GLPs as the backbones of obesity treatments in the future Nov 18, 2025
    Show notes

    He discusses Zealand's partnership with Roche, and new data that will be coming next year. Plus, the company's partnership with Boehringer on survodutide.

    Jefferies London: Nanobiotix has a new platform that is meant to help RNA/DNA-based therapies, gene therapies, oncolytic viruses and other liver-delivered medicines have better efficacy Nov 18, 2025
    Show notes

    CEO Laurent Levy introduces us to the company's Curadigm Nanoprimer platform and explains its potential use cases. Plus, an update on the company's JNJ partnership, and a recent royalty deal.

    Previous 1 16 17 18 19 20 49 Next

    Related Podcasts

    Science Friday

    1

    Science Friday Astronomy
    The Naked Scientists Podcast

    2

    The Naked Scientists Podcast Life Sciences
    Stuff To Blow Your Mind

    3

    Stuff To Blow Your Mind Life Sciences
    Stuff To Blow Your Mind

    4

    Stuff To Blow Your Mind Life Sciences
    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone

    5

    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone Health & Fitness
    All In The Mind

    6

    All In The Mind Government & Organizations
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights